Mechanistic Modeling in Biotherapeutic Drug Development
Mechanistic modeling is revolutionizing biotherapeutic drug development with the goal of getting new medicines to patients faster, more reliably and more cost-effectively.
We are applying our deep understanding of disease biology to design a diverse range of novel modalities that are the foundation for life-changing biotherapeutics for patients.
Antibody therapeutics business partnering PetMedix
Combining PetMedix’ expertise in veterinary biotherapeutic technology with Boehringer Ingelheim’s long experience and innovation in human antibody discovery and development provides a unique opportunity for the partners.
As the world population is projected to reach 9.8 billion in 2050, animal health becomes fundamental to ensure both animal well-being and global protein supply.
We are driven by the desire to improve human and animal health -– now and in the future. Therefore, we have developed our framework: Sustainable Development – For Generations.
Boehringer Ingelheim and the Warren Center for Neuroscience Drug Discovery are partnering to find new medicines for patients with neuropsychiatric disorders.
MORE GREEN: Environmental sustainability at a glance
On Earth Day, we share the progress of our global environmental sustainability MORE GREEN program and what the team is tackling, all 365 days of the year.